GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). As a result of the settlement, GSK must change the way it promotes its diabetes drugs, including Avandia. However, the company did not admit to “any wrongdoing or liability of any kind.” The states charged that GSK did not report some Avandia safety data. They also said the drug manufacturer violated consumer protection laws when it misrepresented heart attack risk with the drug, as well as the safety of its use, alone or in combination with other drugs.